Skip to contentR
REGENXBIO Inc.
R
RGNXREGENXBIO Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$21.21M$21.21Mderived−4.5% vs Q4 2023 Net Income-$51.19M-$51.19MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
REGENXBIO Inc. · CIK 1590877 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$51,368,000N/M Operating Cash Flowderived-$31,624,000N/M Free Cash Flowderived-$32,703,000N/M Margins · derivedOperating margin-242.1%+45.5 pt vs Q4 2023
Net margin-241.3%+41.8 pt vs Q4 2023
ended Dec 31, 2024 · filed Mar 13, 2025 · 72 d after period end